Citations

Showing 10 of 108152 citations.

Current Epigenetic Insights in Kidney Development
Chan, Katrina , Li, Xiaogang

Mayo Clinic

Genes | August 22, 2021 | Volume: 12 | Issue: 8 | Pages: 1281

10.3390/genes12081281 | PMID 34440455 Get It

The kidney is among the best characterized developing tissues, with the genes and signaling pathways that regulate embryonic and adult kidney patterning and development having been extensively identified. It is now widely understood that DNA methylation and histone modification patterns are imprinted during embryonic development and must be maintained in adult cells for appropriate gene transcription and phenotypic stability. A compelling question then is how these epigenetic mechanisms play a role in kidney development. In this review, we describe the major genes and pathways that have been linked to epigenetic mechanisms in kidney development. We also discuss recent applications of single-cell RNA sequencing (scRNA-seq) techniques in the study of kidney development. Additionally, we summarize the techniques of single-cell epigenomics, which can potentially be used to characterize epigenomes at single-cell resolution in embryonic and adult kidneys. The combination of scRNA-seq and single-cell epigenomics will help facilitate the further understanding of early cell lineage specification at the level of epigenetic modifications in embryonic and adult kidney development, which may also be used to investigate epigenetic mechanisms in kidney diseases.
Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment
Mengel, Eugen , Riol, Rosalia Maria Da, Toro, Mireia del , Gautschi, Matthias , Grünewald, Stephanie , Harmatz, Paul , Héron, Bénédicte , Maier, Esther M. , Roubertie, Agathe , Santra, Saikat , Day, Simon , Andreasen, Anne Katrine, Geist, Marie Aavang, Petersen, Nikolaj H.T., Ingemann, Linda, Hansen, Thomas Michael, Blaettler, Thomas , Kirkegaard, Thomas , Dali, Christine í, Patterson, Marc C. , Deodato, Federica , Grønborg, Sabine , Tylki‐Szymańska, Anna , Hansen, Thomas, Mengel, Eugen

Mayo Clinic

Journal of Inherited Metabolic Disease | August 21, 2021 | Volume: 44 | Issue: 6 | Pages: 1463-1480

10.1002/jimd.12428 | PMID 34418116 Get It

AbstractNiemann‐Pick disease type C (NPC) is a rare, genetic, progressive neurodegenerative disorder with high unmet medical need. We investigated the safety and efficacy of arimoclomol, which amplifies the heat shock response to target NPC protein misfolding and improve lysosomal function, in patients with NPC. In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use. Routine clinical care was maintained. Arimoclomol was administered orally three times daily. The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months. Fifty patients enrolled; 42 completed. At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo. A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression. In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006). Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo. Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%). Treatment‐related serious adverse events (n = 2) included urticaria and angioedema. Arimoclomol provided a significant and clinically meaningful treatment effect in NPC and was well tolerated.
Anterior nucleus of the thalamus seizure detection in ambulatory humans
Gregg, Nicholas M. , Marks, Victoria S. , Sladky, Vladimir , Lundstrom, Brian N. , Klassen, Bryan T. , Brinkmann, Benjamin H. , Miller, Kai J. , Gompel, Jamie J. Van , Křemen, Václav , Klassen, Bryan, Messina, Steven A. , Brinkmann, Benjamin H , Van Gompel, Jamie J , Worrell, Gregory A , Kremen, Vaclav , Lundstrom, Brian Nils , Gregg, Nicholas M , Marks, Victoria S , Worrell, Gregory A.

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 10 | Pages: No page available

10.1111/epi.17047 | PMID 34418083 Get It

AbstractThere is a paucity of data to guide anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS) with brain sensing. The clinical Medtronic Percept DBS device provides constrained brain sensing power within a frequency band (power‐in‐band [PIB]), recorded in 10‐min averaged increments. Here, four patients with temporal lobe epilepsy were implanted with an investigational device providing full bandwidth chronic intracranial electroencephalogram (cEEG) from bilateral ANT and hippocampus (Hc). ANT PIB‐based seizure detection was assessed. Detection parameters were cEEG PIB center frequency, bandwidth, and epoch duration. Performance was evaluated against epileptologist‐confirmed Hc seizures, and assessed by area under the precision‐recall curve (PR‐AUC). Data included 99 days of cEEG, and 20, 278, 3, and 18 Hc seizures for Subjects 1–4. The best detector had 7‐Hz center frequency, 5‐Hz band width, and 10‐s epoch duration (group PR‐AUC = .90), with 75% sensitivity and .38 false alarms per day for Subject 1, and 100% and .0 for Subjects 3 and 4. Hc seizures in Subject 2 did not propagate to ANT. The relative change of ANT PIB was maximal ipsilateral to seizure onset for all detected seizures. Chronic ANT and Hc recordings provide direct guidance for ANT DBS with brain sensing.
Nasal‐type T‐cell lymphoma referred as fungal rhinosinusitis: Case report
Almazrouei, Aaesha , Sabri, Alain Michel

Mayo Clinic

Clinical Case Reports | August 21, 2021 | Volume: 9 | Issue: 8 | Pages: No page available

10.1002/ccr3.4669 | PMID 34457291 Get It

AbstractNKTCL is a rare and destructive midline tumor that can be easily misdiagnosed as other more common inflammatory processes. The differential diagnosis of NKTCL should always be kept in mind for any lesion of the paranasal sinuses with atypical presentation and nonresponsive to conventional treatments.
Impaired immunomodulatory capacity in adipose tissue‐derived mesenchymal stem/stromal cells isolated from obese patients
Zhu, Xiangyang , Klomjit, Nattawat , Conley, Sabena M., Ostlie, Megan M., Jordan, Kyra L., Lerman, Lilach O. , Lerman, Lilach O , Klomjit, Nattawat , Lerman, Amir

Mayo Clinic

Journal of Cellular and Molecular Medicine | August 21, 2021 | Volume: 25 | Issue: 18 | Pages: 9051-9059

10.1111/jcmm.16869 | PMID 34418300 Get It

AbstractImmune‐modulatory properties of adipose tissue‐derived mesenchymal stem/stromal cells (MSCs) might be susceptible to metabolic disturbances. We hypothesized that the immune‐modulatory function of MSCs might be blunted in obese human subjects. MSCs were collected from abdominal subcutaneous fat of obese and lean subjects during bariatric or kidney donation surgeries, respectively. MSCs were co‐cultured in vitro for 24 h with M1 macrophages, which were determined as M1or M2 phenotypes by flow cytometry, and cytokines measured in conditioned media. In vivo, lean or obese MSCs (5 × 105), or PBS, were injected into mice two weeks after unilateral renal artery stenosis (RAS) or sham surgeries (n = 6 each). Fourteen days later, kidneys were harvested and stained with M1 or M2 markers. Lean MSCs decreased macrophages M1 marker intensity, which remained elevated in macrophages co‐cultured with obese MSCs. TNF‐α levels were four‐fold higher in conditioned media collected from obese than from lean MSCs. RAS mouse kidneys were shrunk and showed increased M1 macrophage numbers and inflammatory cytokine expression compared with normal kidneys. Lean MSCs decreased M1 macrophages, M1/M2 ratio and inflammation in RAS kidneys, whereas obese MSCs did not. MSCs isolated from lean human subjects decrease inflammatory M1 macrophages both in vivo and in vitro, an immune‐modulatory function which is blunted in MSCs isolated from obese subjects.
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
Wheless, James W. , Miller, Ian , Dlugos, Dennis , Biton, Victor, Cascino, Gregory D. , Sperling, Michael R. , Liow, Kore , Vázquez, Blanca , Segal, Eric , Mauney, Weldon, Desai, Jay , Group, for the DIAZ.001.05 Study, Hogan, R Edward , Sperling, Michael R , Carrazana, Enrique , Miller, Ian , Wheless, James W , Tarquinio, Daniel Charles , Rabinowicz, Adrián L. , Carrazana, Enrique , Group, for the DIAZ.001.05 Study

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 10 | Pages: 2485-2495

10.1111/epi.17041 | PMID 34418086 Get It

Abstract Objective A Phase 3 open‐label safety study (NCT02721069) evaluated long‐term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters. Methods Patients were 6–65 years old with diagnosed epilepsy and seizure clusters despite stable antiseizure medications. The treatment period was 12 months, with study visits at Day 30 and every 60 days thereafter, after which patients could elect to continue. Doses were based on age and weight. Seizure and treatment information was recorded in diaries. Treatment‐emergent adverse events (TEAEs), nasal irritation, and olfactory changes were recorded. Results Of 163 patients in the safety population, 117 (71.8%) completed the study. Duration of exposure was ≥12 months for 81.6% of patients. There was one death (sudden unexpected death in epilepsy) and one withdrawal owing to a TEAE (major depression), both considered unlikely to be related to treatment. Diazepam nasal spray was administered 4390 times for 3853 seizure clusters, with 485 clusters treated with a second dose within 24 h; 53.4% of patients had monthly average usage of one to two doses, 41.7% two to five doses, and 4.9% more than five doses. No serious TEAEs were considered to be treatment related. TEAEs possibly or probably related to treatment ( n = 30) were most commonly nasal discomfort (6.1%); headache (2.5%); and dysgeusia, epistaxis, and somnolence (1.8% each). Only 13 patients (7.9%) showed nasal irritation, and there were no relevant olfactory changes. The safety profile of diazepam nasal spray was generally similar across subgroups based on age, monthly usage, concomitant benzodiazepine therapy, or seasonal allergy/rhinitis. Significance In this large open‐label safety study, the safety profile of diazepam nasal spray was consistent with the established profile of rectal diazepam, and the high retention rate supports effectiveness in this population. A second dose was used in only 12.6% of seizure clusters.
Benzodiazepine administration patterns before escalation to second‐line medications in pediatric refractory convulsive status epilepticus
Sheehan, Theodore , Amengual‐Gual, Marta , Vasquez, Alejandra , Abend, Nicholas S. , Anderson, Anne E. , Arya, Ravindra , Aguilar, Cristina Barcia , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Jackson, Michele , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Reece, Latania, Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Shellhaas, Renée A. , Smith, Garnett , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Arya, Ravindra , Barcia Aguilar, Cristina , Farias-Moeller, Raquel , Gaillard, William D , Gaínza-Lein, Marina , Guerriero, Rejean M , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Shellhaas, Renée A , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Sheehan, Theodore , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 11 | Pages: 2766-2777

10.1111/epi.17043 | PMID 34418087 Get It

Abstract Objective This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non‐BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE). Methods This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non‐BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non‐BZD ASM. Results We included 293 patients with a median (interquartile range) age of 3.8 (1.3–9.3) years. Thirty‐six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997–.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out‐of‐hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73–3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40–6.03, p < .0001) compared to patients with in‐hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01–2.06, p = .04). Forty‐seven percent of patients ( n = 94) with out‐of‐hospital onset did not receive treatment before hospital arrival. Among patients with out‐of‐hospital onset who received at least two BZDs before hospital arrival ( n = 54), 48.1% received additional BZDs at hospital arrival. Significance Failure to escalate from BZDs to non‐BZD ASMs occurs mainly in out‐of‐hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non‐BZD ASMs after two BZD doses during handoffs between prehospital and in‐hospital settings.
High-Sensitivity Troponin: Revealing the Ominous Implications of Myocardial Injury in Critical Illness*
Ahmed, Abdelrahman , Jaffe, Allan S. , Ahmed, Abdelrahman M, Jaffe, Allan S. , Wiley, Brandon M.

Mayo Clinic

Critical Care Medicine | August 21, 2021 | Volume: 49 | Issue: 9 | Pages: 1572-1575

10.1097/ccm.0000000000005048 | PMID 34413271 Get It

Migration of Hyaluronic Acid–Based Soft Tissue Filler From the Temples to the Cheeks—An Anatomic Explanation
Almukhtar, Rawaa , Fabi, Sabrina G. , Fitzgerald, Rebecca, Cotofana, Sebastian

Mayo Clinic

Dermatologic Surgery | August 21, 2021 | Volume: 47 | Issue: 11 | Pages: 1526-1527

10.1097/dss.0000000000003219 | PMID 34417376 Get It

Anterior Cruciate Ligament Reconstruction Does Not Impact Career Earnings After Return to Play in National Basketball Association Athletes
Khalil, Lafi S. , Rahman, Tahsin , Abbas, Leena, Akioyamen, Noel O. , Farley, Brendan J., Bazzi, Talal, Okoroha, Kelechi R. , Abbas, Muhammad J. , Bazzi, Talal

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | August 21, 2021 | Volume: 3 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2021.07.010 | PMID 34712986 Get It

Purpose To quantify the financial impact of an anterior cruciate ligament (ACL) injury on the remaining career earnings of National Basketball Association (NBA) players. Methods We performed a retrospective review of all NBA players who had an ACL rupture between 2000 and 2019. Players were matched to healthy controls by age, position, body mass index, and player efficiency rating at the time of injury (index year). Player information collected included demographic information, position, team role, draft pick, date of injury, contract length, and earnings during the 3 years before and 7 years after the index year, as well as new contract length and earnings after injury. Results A total of 12 players (22%) did not return to play (RTP). No statistically significant difference in annual earnings was present at any time point between cohorts. When we examined the mean difference in earnings between the first 3 post‐index seasons and the 3 pre‐index seasons, both the ACL and control cohorts showed increased salaries as players’ careers progressed, without a significant difference in earnings. When comparing cohorts, we found no significant difference in the length and earnings of contracts during the index year. Furthermore, there was no significant difference in the length or earnings of the first new contract signed after the index year between cohorts. Additionally, NBA players who were able to RTP after ACL reconstruction were more likely to experience increased earnings if they had greater experience and performance prior to their injury ( P < .01). Conclusions Our study found that NBA players did not experience diminished earnings after RTP from an ACL reconstruction when compared with matched controls. Furthermore, no differences were seen in lengths of new contracts or in contract earnings between cohorts. Players with greater experience and performance prior to injury were more likely to have increased earnings after ACL reconstruction. Level of Evidence Level III, retrospective case‐control study.